COV Share Price Performance
Recent COV News & Updates
No updates
Cleo Diagnostics Ltd Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.024
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,469.73%
- Debt/Equity Ratio
- 0%
Cleo Diagnostics Ltd Competitors
About COV
- Founded
- 2021
- Employees
- n/a
- CEO
- WebsiteView website
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents. The company was incorporated in 2021 and is based in Melbourne, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.5%
- 1 Year: 8.6%
- Year to Date: 5.1%
The market has been flat in the last week, however the Materials sector is down 4.2%. As for the longer term, the market has risen 8.6% in the past 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading